TY - JOUR
T1 - Hepatocyte autotaxin expression promotes liver fibrosis and cancer
AU - Kaffe, Eleanna
AU - Katsifa, Aggeliki
AU - Xylourgidis, Nikos
AU - Ninou, Ioanna
AU - Zannikou, Markella
AU - Harokopos, Vaggelis
AU - Foka, Pelagia
AU - Dimitriadis, Alexios
AU - Evangelou, Kostas
AU - Moulas, Anargyros N.
AU - Georgopoulou, Urania
AU - Gorgoulis, Vassilis G.
AU - Dalekos, George N.
AU - Aidinis, Vassilis
N1 - Publisher Copyright:
© 2016 by the American Association for the Study of Liver Diseases.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Autotaxin (ATX) is a secreted lysophospholipase D that catalyzes the production of lysophosphatidic acid (LPA), a pleiotropic growth-factor–like lysophospholipid. Increased ATX expression has been detected in various chronic inflammatory disorders and different types of cancer; however, little is known about its role and mode of action in liver fibrosis and cancer. Here, increased ATX expression was detected in chronic liver disease (CLD) patients of different etiologies, associated with shorter overall survival. In mice, different hepatotoxic stimuli linked with the development of different forms of CLDs were shown to stimulate hepatocyte ATX expression, leading to increased LPA levels, activation of hepatic stellate cells (HSCs), and amplification of profibrotic signals. Hepatocyte-specific, conditional genetic deletion and/or transgenic overexpression of ATX established a liver profibrotic role for ATX/LPA, whereas pharmacological ATX inhibition studies suggested ATX as a possible therapeutic target in CLDs. In addition, hepatocyte ATX ablation and the consequent deregulation of lipid homeostasis was also shown to attenuate hepatocellular carcinoma (HCC) development, thus implicating ATX/LPA in the causative link of cirrhosis and HCC. Conclusion: ATX is a novel player in the pathogenesis of liver fibrosis and cancer and a promising therapeutic target. (Hepatology 2017;65:1369-1383).
AB - Autotaxin (ATX) is a secreted lysophospholipase D that catalyzes the production of lysophosphatidic acid (LPA), a pleiotropic growth-factor–like lysophospholipid. Increased ATX expression has been detected in various chronic inflammatory disorders and different types of cancer; however, little is known about its role and mode of action in liver fibrosis and cancer. Here, increased ATX expression was detected in chronic liver disease (CLD) patients of different etiologies, associated with shorter overall survival. In mice, different hepatotoxic stimuli linked with the development of different forms of CLDs were shown to stimulate hepatocyte ATX expression, leading to increased LPA levels, activation of hepatic stellate cells (HSCs), and amplification of profibrotic signals. Hepatocyte-specific, conditional genetic deletion and/or transgenic overexpression of ATX established a liver profibrotic role for ATX/LPA, whereas pharmacological ATX inhibition studies suggested ATX as a possible therapeutic target in CLDs. In addition, hepatocyte ATX ablation and the consequent deregulation of lipid homeostasis was also shown to attenuate hepatocellular carcinoma (HCC) development, thus implicating ATX/LPA in the causative link of cirrhosis and HCC. Conclusion: ATX is a novel player in the pathogenesis of liver fibrosis and cancer and a promising therapeutic target. (Hepatology 2017;65:1369-1383).
UR - http://www.scopus.com/inward/record.url?scp=85012077061&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012077061&partnerID=8YFLogxK
U2 - 10.1002/hep.28973
DO - 10.1002/hep.28973
M3 - Article
C2 - 27981605
AN - SCOPUS:85012077061
SN - 0270-9139
VL - 65
SP - 1369
EP - 1383
JO - Hepatology
JF - Hepatology
IS - 4
ER -
